Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Enrollment Complete
Learn More
Press Releases
Jun 15, 2023
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting
Read More
May 18, 2023
Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
Read More
